Former BU innovator of the year– Professor and Chief of Computational Biomedicine in the Department of Medicine, Dr. Avi Spira, M.D, Ph.D., has come up with a new biomarker signature to improve the treatment of Chronic Obstructive Pulmonary Disease (COPD), which affects 14.8 million individuals in the United States, and is predicted to become the third leading cause of death by 2030. Given the complexity of this disease, there are no disease modifying agents available. According to Dr. Spira, this is largely due to the fact that “very little is known about the molecular mechanisms underlying COPD pathogenesis and progression”. Dr. Spira and his team including Associate Professor Marc Lenburg, Ph.D. and Assistant Professor Katrina Steiling Ph.D. used whole-genome expression profiling on bronchial brushings from smokers with and without COPD is used to identify the gene signature that associated with COPD. 98 genes were identified whose expression levels were associated with COPD disease state and were reversible with effective treatment.
“We think our 98 air way gene signature can serve as a biomarker that reflects the presence of COPD and severity of lung function impairment,” says Dr. Lenburg.
According to the team, this technology could also be used to shorten the clinical development timeline by serving as biomarker of patient response to COPD therapy. As an Attending in the Medical Intensive Care Unit at Boston Medical Center, Dr. Spira notes that another impediment to developing effective therapies is that currently clinicians use lung function test to determine if patients are responding to therapy, which requires at and at least six months after medication to evaluate the effect.
“Preliminary results suggest that our airway gene signature may work as an intermediate biomarker of response to COPD therapy, and could significantly reduce the time needed to observe and evaluate the effectiveness of COPD medications” says Dr. Steiling.
While the lab continues to advance this and other programs, BU OTD is currently seeking a commercial partner to develop the COPD biomarker signature.
Dr. Spira is also the founder and scientific advisor to AllegroDx Inc., a molecular diagnostics company focused on the development and commercialization of innovative genomic tests to support the diagnosis and management of lung cancer.
For partnering opportunities, please contact:
April Effort
Director, Business Development, Life Sciences
Dear Reader,
Carmela Abraham’s work with the protein Klotho has provided a potential method of alleviating cognitive decline in aging organisms. In the lab, Abraham discovered a deficiency of Klotho in aging monkeys and mice, which seemed to correlate with the development of cognitive decline. Furthermore, she found that overexpression of Klotho resulted in a 30% increase in lifespan of transgenic mice. Her proposed product would utilize these findings to improve the overall health and mental well-being of any organism by elevating its levels of Klotho.
Gerald Denis has used genetic manipulation of the BET protein family to uncouple obesity from Type-2 Diabetes and inflammation. They have produced mice that are metabolically healthy despite being severely obese—by suppressing the expression of Brd2 (a member of the BET family), these mice are protected from Type-2 Diabetes. Denis proposes to use these findings to produce a few BET inhibitor compounds which could help prevent or alleviate those at risk (or suffering from) Type-2 Diabetes.
As Boston University’s Director of New Ventures at the Office of Technology Development, my focus is to help build new companies based on technologies being created at the University. I was excited by the tremendous interest of faculty in participating in the creation of new ventures. I’ve found our experienced researchers are keen on finding new ways to impact society and translate their cutting-edge research into influential ventures. BU thrives on the spirit of “One BU,” where an engaged and collaborative community is also helping to create fertile ground for cultivating the next big idea.
Lung cancer is diagnosed in over 220,000 patients in the U.S. every year, and results in more cancer deaths than breast, colorectal, and prostate cancers combined. If detected at an early-stage, lung cancer can be treated using standard of care surgery. Most of these patients treated with surgery have reduced lung function and surgeons would prefer to remove less lung tissue from around the margins of the tumor rather than compromising the patient’s lung function further. However, the smaller the margin removed from around the tumor, the higher the risk of recurrent disease. Systemic chemotherapy and radiation therapies are not effective for early stage patients and have significant negative side effects. Unfortunately, even with the best available treatment, about half of the 50,000 early stage patients treated annually with surgery, will develop a fatal recurrence. Clinician and patients are desirous of new and more effective localized, low toxicity treatment options which can prevent cancer recurrence.
Founded in 2008, AcuityBio started as a collaborative effort by Boston University’s Dr. Mark Grinstaff (Professor of Chemistry) and Brigham and Women’s Hospital Dr. Yolanda Colson (Cardiothoracic oncology Surgeon and Scientist) to improve the current standard of care for lung cancer patients and address the major clinical problem of tumor recurrence. Their goal was to create a unique and simple-to-use drug-loaded implant that could reduce cancer recurrence by locally delivering therapeutic levels of drug to residual tumor cells for extended periods of time. Utilizing Colson’s experience in surgical oncology and Grinstaff’s knowledge in polymer chemistry and engineering, the team developed the ABC MeshTM. Together with Jesse Wolinsky, a post-doctoral researcher in Grinstaff’s lab, the team published several papers on the technology in March of 2010. A few months later, First Founders Ltd. introduced Dr. Jay Schwartz to the inventor team to act as the new company’s CEO. AcuityBio’s biocompatible and biodegradable ABC MeshTM will be stapled in at the edge of the resection during normal tumor removal surgery and deliver chemotherapeutic drug locally to the tissue over 50 days and then be absorbed by the body. By localizing the administration of chemotherapeutic agent, the optimal dose of drug can be delivered over a time span where it will be most effective and result in little to no side effects. The ABC MeshTM technology has come a long way from its inception and will be headed to the clinic within two years.